4basebio plc (4BB) ORD EUR1
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
4basebio client gets approval to start trial in Australia
21 March 2024 16:11
(Sharecast News) - Synthetic DNA product developer 4basebio announced on Thursday that its client, Helix Nanotechnologies, has achieved a significant milestone with the receipt of HREC approval in Australia.
-
4basebio inks significant DNA supply contract
1 March 2024 13:42
(Sharecast News) - 4basebio announced a significant contract through a competitive tender process on Friday, to provide research and GMP-grade synthetic DNA for the advancement of RNA therapeutics and...
-
First-half losses narrow for 4basebio
21 September 2023 13:56
(Sharecast News) - Biotechnology company 4basebio reported revenues from its DNA and Hermes products surpassing £0.2m in its first half on Thursday.
-
4basebio inks supply deal with Italy's Neomatrix
25 May 2023 15:40
(Sharecast News) - Synthetic DNA biotechnology specialist 4basebio announced a product supply agreement with Neomatrix on Thursday, which it described as an Italian biotech focussed on personalised cancer...
-
4basebio enters neurofibromatosis collaboration with two universities
10 June 2022 12:17
(Sharecast News) - Life sciences company 4basebio announced a collaboration with the University of Alabama (UA) and Teesside University (TU) on Friday, in a research project aimed at developing an effective...
-
Losses to continue as 4basebio focuses on commercialisation
9 May 2022 11:34
(Sharecast News) - Specialist DNA-focussed life sciences company 4basebio reported revenue of £0.34m in its final results on Monday, down from £0.46m year-on-year.
-
4basebio inks development deal with Heqet Therapeutics
27 April 2022 12:34
(Sharecast News) - Life sciences company 4basebio announced a joint development agreement with Heqet Therapeutics on Wednesday.
-
4basebio launches two new synthetic DNA products
23 March 2022 15:23
(Sharecast News) - Cell and gene therapy developer 4basebio announced the expansion of its synthetic DNA product offering on Wednesday.
-
4basebio makes progress with manufacturing development
15 February 2022 12:54
(Sharecast News) - Specialist life sciences company 4basebio updated the market on its synthetic DNA business on Tuesday, having added Mark Cooper its as head of manufacturing in December, alongside further...
-
4basebio enters research collaboration with eTheRNA
18 January 2022 14:41
(Sharecast News) - Cell and gene therapy intellectual property company 4basebio announced a strategic research collaboration between its wholly-owned subsidiary 4basebio Discovery and eTheRNA immunotherapies...
-
4basebio enters development deal with T-cell therapy firm Leucid
23 November 2021 13:57
(Sharecast News) - Life sciences company 4basebio announced a joint development agreement between its wholly owned-subsidiary 4basebio Discovery and Leucid Bio on Tuesday, which it said was pioneering...
-
4basebio files for patent on novel DNA type
22 June 2021 08:52
(Sharecast News) - Specialist gene therapy life sciences company 4basebio UK has filed a patent application for a novel protected and stabilised linear synthetic DNA type, dubbed 'osDNA', it...
Company announcements Announcements
-
4basebio awarded tender to deliver research and GMP-grade synthetic DNA in CPI's tender process for supplying its RNA Centre of
1 March 2024 07:00
4basebio
-
Holding(s) in Company
6 February 2024 07:01
4basebio
-
Holding(s) in Company
6 February 2024 07:01
4basebio
-
Holding(s) in Company
6 February 2024 07:01
4basebio
-
Holding(s) in Company
6 February 2024 07:01
4basebio
-
Exercise of Options
6 February 2024 07:00
4basebio
-
Holding(s) in Company
5 February 2024 07:01
4basebio
-
Holding(s) in Company
5 February 2024 07:01
4basebio
-
Holding(s) in Company
5 February 2024 07:01
4basebio
-
Directors' Dealings
5 February 2024 07:00
4basebio
-
Long-Term Incentive Plan and Exercise of Options
2 February 2024 07:00
4basebio
-
Half-year Report
21 September 2023 07:00
4basebio
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.